Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
nL-ATN1-001 for DRPLA
NCT07221760Phase 2Active, not recruiting
- Sponsor
- n-Lorem Foundation
- Start
- Nov 2025
- Primary completion
- Nov 2027
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nL-ATN1-001 in dentatorubral-pallidoluysian atrophy (DRPLA), sponsored by n-Lorem Foundation. Primary endpoint: Seizures at 24 months. Started Nov 2025; status: active, not recruiting.
02
Drugs
nL-ATN1-001
03
Conditions
dentatorubral-pallidoluysian atrophy (DRPLA)
Beyond the preview
Go deeper on NCT07221760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07221760.